share_log

Canopy Growth | 8-K: Canopy Growth Reports Fourth Quarter and Fiscal Year 2024 Financial Results; Q4 FY2024 Net Revenue increased 7% year-over-year, or 16% excluding divested businesses

Canopy Growth | 8-K: Canopy Growth Reports Fourth Quarter and Fiscal Year 2024 Financial Results; Q4 FY2024 Net Revenue increased 7% year-over-year, or 16% excluding divested businesses

Canopy Growth | 8-K:Canopy Growth公布第四季度和2024财年财务业绩;第四季度 FY2024 净收入同比增长7%,不包括剥离的业务,增长16%
美股SEC公告 ·  05/30 07:13
Moomoo AI 已提取核心信息
On May 30, 2024, Canopy Growth Corporation, a leading cannabis company, announced its financial results for the fourth quarter and fiscal year ended March 31, 2024. The report highlighted a 7% increase in Q4 FY2024 net revenue year-over-year, with a notable 43% increase in net revenue from Storz & Bickel, driven by strong sales of the new Venty portable vaporizer. The Canadian medical cannabis net revenue also saw a 16% increase in Q4 FY2024 and a 10% increase for the full fiscal year. The company's cost reduction actions led to a 54% decrease in Canada cannabis Cost of Goods Sold for the fiscal year compared to the previous year. Canopy Growth's balance sheet was strengthened with no material debt obligations due until March 2026. The company's CEO, David Klein, emphasized...Show More
On May 30, 2024, Canopy Growth Corporation, a leading cannabis company, announced its financial results for the fourth quarter and fiscal year ended March 31, 2024. The report highlighted a 7% increase in Q4 FY2024 net revenue year-over-year, with a notable 43% increase in net revenue from Storz & Bickel, driven by strong sales of the new Venty portable vaporizer. The Canadian medical cannabis net revenue also saw a 16% increase in Q4 FY2024 and a 10% increase for the full fiscal year. The company's cost reduction actions led to a 54% decrease in Canada cannabis Cost of Goods Sold for the fiscal year compared to the previous year. Canopy Growth's balance sheet was strengthened with no material debt obligations due until March 2026. The company's CEO, David Klein, emphasized the focus on cannabis and momentum in the industry, with growth opportunities in Germany and the United States. CFO Judy Hong highlighted the significant progress in reducing expenses, cash burn, and debt, moving the company towards positive Consolidated Adjusted EBITDA. The financial report also included details on the company's segments, with Storz & Bickel and Canada medical cannabis showing strong performance. The report concluded with statements on forward-looking expectations and strategies for growth.
2024年5月30日,领先的大麻公司Canopy Growth Corporation公布了截至2024年3月31日的第四季度和财年的财务业绩。该报告强调,受新款Venty便携式蒸发器的强劲销售推动,第四季度 FY2024 净收入同比增长7%,Storz & Bickel的净收入显著增长了43%。加拿大医用大麻净收入在 FY2024 第四季度也增长了16%,整个财年增长了10%。该公司的成本削减行动使本财年加拿大大麻的商品销售成本与去年同期相比下降了54%。Canopy Growth的资产负债表得到加强,2026年3月之前没有实质性债务到期。该公司首席执行官戴维·克莱因强调了对大麻的关注和该行...展开全部
2024年5月30日,领先的大麻公司Canopy Growth Corporation公布了截至2024年3月31日的第四季度和财年的财务业绩。该报告强调,受新款Venty便携式蒸发器的强劲销售推动,第四季度 FY2024 净收入同比增长7%,Storz & Bickel的净收入显著增长了43%。加拿大医用大麻净收入在 FY2024 第四季度也增长了16%,整个财年增长了10%。该公司的成本削减行动使本财年加拿大大麻的商品销售成本与去年同期相比下降了54%。Canopy Growth的资产负债表得到加强,2026年3月之前没有实质性债务到期。该公司首席执行官戴维·克莱因强调了对大麻的关注和该行业的势头,德国和美国也有增长机会。首席财务官朱迪·洪强调了在减少开支、现金消耗和债务方面取得的重大进展,这使公司实现了正的合并调整后息税折旧摊销前利润。财务报告还包括公司细分市场的详细信息,Storz & Bickel和加拿大医用大麻表现强劲。报告最后发表了关于前瞻性预期和增长战略的陈述。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息